Abstracts Archive - Page 163 of 2607 - ACR Meeting Abstracts

Abstract Number: 0581 • ACR Convergence 2025
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Philip J. Mease¹, Álvaro González Cantero², Jennifer Soung³, April Armstrong⁴, Joseph F Merola⁵, Fabian Proft⁶, Laure Gossec⁷, Dafna D. Gladman⁸, Laura Coates⁹, Lichen Teng¹⁰, Jimena Vázquez¹¹, Cynthia Deignan¹² and Arthur Kavanaugh¹³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain, ³Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁴University of California Los Angeles, Los Angeles, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ¹⁰Amgen Inc., Thousand Oaks, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Amgen, Inc., Agoura Hills, CA, ¹³University of California, San Diego, School of Medicine, San Diego, CA
Background/Purpose: The prevalence of cardiometabolic diseases, including obesity and diabetes, is higher in patients with psoriatic arthritis (PsA) than those without PsA.1,2 Metabolic syndrome is…
Abstract Number: 0653 • ACR Convergence 2025
In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at their Clinical Dose Regimens
May-Linda Lepage¹, Patrick Nolain¹, Céline Cottereaux¹, Emilie Lagoutte¹, Justine Dao¹, Adrien Cosson¹, Laetitia Furio¹, Willem Hettema², Chantal Tasset³, Roland Blanqué¹, Isabelle Parent¹ and René Galien¹, ¹Galapagos SASU, Paris, France, ²Galapagos B.V., Leiden, Netherlands, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: Tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member, is attracting a lot of interest as a new target to treat patients with…
Abstract Number: 0649 • ACR Convergence 2025
Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Zhuoli Zhang¹, Shengyun Liu², Min Yang³, Yasong Li⁴, Qinghong Yu⁵, Xinwang Duan⁶, Qiang Shu⁷, Qibing Xie⁸, Yanfei Chen⁹, Daming Ou¹⁰, Lan He¹¹, Hongbin Li¹², Pingting Yang¹³, Juan Li¹⁴, Terry Yan¹⁵, Xin He¹⁶, Daniel Moldaver¹⁷, Ciara O'Shea¹⁸ and Liya Fan¹⁶, ¹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ³Nanfang Hospital Southern Medical University, Guangzhou, China (People's Republic), ⁴Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁵Zhujiang Hospital of Southern Medical University, Zhujiang, China (People's Republic), ⁶The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷Qilu Hospital of Shandong University, Jinan, China (People's Republic), ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic), ⁹The First Hospital of Lanzhou University, Lanzhou, China (People's Republic), ¹⁰The First Affiliated Hospital of University of South China, Hengyang, China (People's Republic), ¹¹The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic), ¹²The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹³The First Hospital of China Medical University, Shenyang, China (People's Republic), ¹⁴The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ¹⁵Medical Affairs, GSK, Shanghai, China (People's Republic), ¹⁶VEO, GSK, Shanghai, China (People's Republic), ¹⁷GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ¹⁸Global Medical Affairs, GSK, Dublin, Ireland
Background/Purpose: Belimumab, a B-cell modulator monoclonal antibody that selectively inhibits BLyS and reduces autoreactive B-cells that drive lupus disease activity, has consistently demonstrated improved efficacy…
Abstract Number: 0678 • ACR Convergence 2025
Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Andrea-Hermina Györfi¹, Ayla Nadja Stuetz², Christina Duesing³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Yi-Nan Li⁶, Celine van Saan⁵, Alexandru-Emil Matei⁷, Alexander Hoelscher⁵, Peter-Martin Bruch⁸, Sarah Koziel⁸, Manuel Roehrich⁹, Mareike Cramer¹⁰, Bernhard Homey⁵, Bjoern Buehring¹¹, Alexander Kreuter¹², Aleksandar Radujkovic⁵, Claus Peter Heußel¹³, Hanns-Martin Lorenz¹⁴, Ricardo Grieshaber-Bouyer¹⁵, Georg Schett¹⁶, Jörg Distler¹⁷ and Wolfgang Merkt¹⁸, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Klinik für Rheumatologie, Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶University Hospital of Düsseldorf, Düsseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁸University Hospital Düsseldorf, Dusseldorf, Germany, ⁹Universitätsmedizin Mainz, Mainz, ¹⁰University Hospital Düsseldorf, Düsseldorf, Germany, ¹¹Bergisches Rheuma-Zentrum, Krankenhaus St Josef, Wuppertal, Germany, ¹²HELIOS St. Elisabeth Clinic Oberhausen, University Witten-Herdecke, Oberhausen, Germany, ¹³Thoraxklinik, University of Heidelberg, Heidelberg, ¹⁴Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹⁵University Hospital Erlangen, Erlangen, Germany, ¹⁶Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) possesses the highest case-related mortality of all rheumatic diseases. B cell-targeting, including CD19-targeting CAR-T cells, has shown efficacy but failed to…
Abstract Number: 0568 • ACR Convergence 2025
Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
caroline Damen¹, Philippe Carron², Ann-Sophie De Craemer³, Filip Van den Bosch³ and Dirk Elewaut⁴, ¹Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ²Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁴VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium
Background/Purpose: Peripheral spondyloarthritis (pSpA) is a neglected clinical entity with few therapeutic or clinical management trials available to date. In the CRESPA-trial (1) very early…
Abstract Number: 0590 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Vinod Chandran¹, Oliver FitzGerald², Philip J. Mease³, Lihi Eder⁴, Jose Scher⁵, Christopher Ritchlin⁶, Dafna D. Gladman⁷, Walter P Maksymowych⁸, Coryandar Gilvary⁹, Aditi Basu Bal⁹, Eleni Vritzali¹⁰ and Jinqi Liu⁹, ¹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ²UCD, Dublin ⁶, Dublin, Ireland, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto, ON, Canada, ⁵New York University School of Medicine, New York, NY, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Understanding how treatments affect disease-relevant biomarker expression is essential for advancing targeted therapies. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, has…
Abstract Number: 0679 • ACR Convergence 2025
Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation
Parisa Mazrooei, Xuting Rebecca Sheng, Xiaoyun Yang, Lyrialle Han, Samira Jamalian, Daniel Repplinger, Jingxuan He, Evelin Logis, Jeongsup Shim, Angela Hendricks, Lena Wang, Andrew Thorley and Sara Glickstein, Genentech/Roche, South San Francisco
Background/Purpose: There are 3 isoforms of Transforming Growth Factor Beta (TGFb), a cytokine frequently upregulated in fibrosis. Chronic targeting of TGFb1 and TGFb2 for fibrotic…
Abstract Number: 0592 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Julio Ramírez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Rajan Bajracharya¹², Patrik Öhagen¹³, Christine de La Loge¹⁰ and William Tillett¹⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Slough, England, United Kingdom, ¹³UCB, Stockholm, Sweden, ¹⁴Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal…
Abstract Number: 0688 • ACR Convergence 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Benjamin Chaigne¹, Alexandre bense², Frédérique Aubourg³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Gregory Pugnet⁶, Eric Hachulla⁷, Vincent Cottin⁸, Arnaud Hot⁸, bertrand Dunogue¹, Anuxcy Kanagaratnam², Sylvain Palat⁹, Alain Lescoat¹⁰, Sabine berthier¹¹, Emmanuel Chatelus¹², Sébastien Rivière¹³, David Launay¹⁴, Marie-Elise Truchetet¹⁵, Anh-Tuan Dinh-Xuan³ and Luc Mouthon¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²AP HP, Paris, France, ³Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Montpelliers, France, ⁷CHU, Lilles, France, ⁸CHU, Lyon, France, ⁹Limoges, Limoges, France, ¹⁰CHU Rennes - University Rennes, Rennes, France, ¹¹CHU, Dijon, France, ¹²Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹³AP HP, Parsi, France, ¹⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ¹⁵Bordeaux University Hospital, Bordeaux, France
Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
Abstract Number: 0677 • ACR Convergence 2025
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
Jessica Fairley¹, Elizabeth Paratz², Dylan Hansen³, Susanna Proudman⁴, Joanne Sahhar⁵, Gene-Siew Ngian⁶, Diane Apostolopoulos⁶, Jennifer Walker⁷, Lauren Host⁸, Wendy Stevens¹, Andre La Gerche², Mandana Nikpour⁹ and Laura Ross¹, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Monash Health, Melbourne, Victoria, Australia, ⁶Monash University, Melbourne, Victoria, Australia, ⁷Flinders University, Adelaide, Victoria, Australia, ⁸Fiona Stanley Hospital, Perth, Victoria, Australia, ⁹University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…
Abstract Number: 0576 • ACR Convergence 2025
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Laura Coates¹, Philip J. Mease², Joseph Merola³, Lourdes Perez Chada⁴, Dafna D. Gladman⁵, Alen Zabotti⁶, Ulrich Mrowietz⁷, mitsumasa kishimoto⁸, Cynthia Deignan⁹, Siddharth Chaudhari¹⁰, Lichen Teng¹¹ and Laure Gossec¹², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Harvard Medical School, Wayland, MA, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ⁷Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Amgen, Inc., Agoura Hills, CA, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Amgen Inc., Thousand Oaks, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: FOREMOST (NCT03747939)1 offers novel insights on early oligoarticular (oligo, ≤4 active joints) PsA. Our aim was to analyse progression to polyarticular (poly; >4 active…
Abstract Number: 0594 • ACR Convergence 2025
Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways
Holme Vestin¹, Nina Oparina¹, Maija-Leena Eloranta¹, Martina Frodlund², Iva Gunnarsson³, Chrisopher Sjöwall², Elisabet Svenungsson⁴, Lars Rönnblom¹, Juliana Imgenberg-Kreuz¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The pathogenesis of SLE involves genetic, environmental and epigenetic factors (1). Increased levels of Bisphenol A (BPA) have been observed in the urine of…
Abstract Number: 0570 • ACR Convergence 2025
Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Gilad Halpert¹, Eri Govrin¹, Omer Gendelman¹, Abdulla Watad², Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: A substantial number of patients with rheumatic inflammatory/autoimmune diseases, do not achieve adequate symptom control with current standard-of-care therapies, including biologics. The endocannabinoid system…
Abstract Number: 0683 • ACR Convergence 2025
Symptom-Based Clustering of Gastrointestinal Involvement in Systemic Sclerosis
Ali Ayla¹, Ernesto Calderon Martinez², Meng Zhang³, Claudia Pedroza⁴, Bingrui Chen⁵, Ashish Balar⁵, Michael Hughes⁶, Silvia Bellando Randone⁷, Brian Skaug¹, Maureen Mayes⁸, Shervin Assassi⁹ and Zsuzsanna McMahan¹⁰, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Division of Rheumatology, Houston, ⁴UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ⁵UTHealth Houston, Houston, TX, ⁶Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁷University of Florence, Florence, Italy, ⁸UT Health Houston Division of Rheumatology, Houston, TX, ⁹Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ¹⁰UT Health Houston, Houston, TX
Background/Purpose: Virtually all patients with systemic sclerosis (SSc) experience gastrointestinal (GI) manifestations over the course of their disease, affecting any region from the mouth to…
Abstract Number: 0684 • ACR Convergence 2025
Translation to Spanish and Linguistic Validation of the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP)
Antonia Valenzuela¹, Adriana Miguel Alvarez², Patricia E. Carreira³, Alejandra Babini⁴, Diana Rocío Gil Calderón⁵, John Pauling⁶ and Tatiana Rodriguez-Reyna², ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁴Hospital Italiano, Córdoba, Argentina, ⁵Hospital Universitario Mayor MEDERI, Universidad del Rosario, Artmedica SAS, Bogotá, Colombia, ⁶North Bristol NHS Trust, Bristol, United Kingdom
Background/Purpose: Systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP) significantly impacts patients’ quality of life, yet validated tools to assess this condition in Spanish-speaking populations are lacking. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].